Cyclerion shareholders approve merger proposals; 1-for-7 reverse split; redomestication fails

Cyclerion Therapeutics, Inc.

Shareholders approved Nasdaq issuance, authorized share increase to 700M, reverse split, and 2026 stock plans; redomestication to Cayman failed.
Board set reverse split at 1-for-7, cutting shares from ~4.7M to ~0.7M; fractional shares paid in cash.
Combined company to trade as Korsana Biosciences, Inc. (KRSA) on Nasdaq from Sept 9, 2026, with new CUSIP 23255M303.
Redomestication failure not a condition to close; merger remains pending with closing conditions to be satisfied.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.